Cardiovascular risk reduction among African Americans: A call to action

Journal of the National Medical Association

Volumn 100, Issue 1, 2008, Pages 18-27

  Watson, Karol E ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCLA Program in Preventive Cardiology

Author keywords

African Americans; Cardiovascular disease; Diabetes mellitus; Hypertension; Statins

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

AFRICAN AMERICAN; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DYSLIPIDEMIA; ETHNIC GROUP; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; OBESITY; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RACE; RISK REDUCTION; SOCIOLOGY;

EID: 38949150069     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0027-9684(15)31170-6     Document Type: Article

References (71)

1. National Center for Health Statistics. Health, United States, 2006 with Chartbook on Trends in the Health of Americans. Hyattsville, MD; 2006.
2. Centers for Disease Control and Prevention. Disparities in premature deaths from heart disease: 50 states and the District of Columbia, 2001. Morb Mortal Wkly Rep. 2004;53:121-125.
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001 ;285:2486-2497.
4. Barnett E, Halverson J. Disparities in premature coronary heart disease mortality by region and urbanicity among black and white adults ages 35-64, 1985-1995. Public Health Rep. 2000;115:52-64.
5. Cooper R, Cutler J, Desvigne-Nickens P, et al. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the National Conference on Cardiovascular Disease Prevention. Circulation. 2000;102:3137-3147.
6. Centers for Disease Control and Prevention. Decline in deaths from heart disease and stroke: United States, 1900-1999. Morb Mortal Wkly Rep. 1999;48:649-656.
7. Clark LT, Ferdinand KC, Flack JM, et al. Coronary heart disease in African Americans. Heart Dis. 2001;3:97-108.
8. Goff DC Jr, Bertoni AG, Kramer H, et al. Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium. Circulation. 2006;113:647-656.
9. Smith SC Jr, Clark LT, Cooper RS, et al. Discovering the full spectrum of cardiovascular disease. Minority Health Summit 2003: report of the Obesity, Metabolic Syndrome, and Hypertension Writing Group. Circulation. 2005;111:e134-e139.
10. Carnethon MR, Bertoni AG, Shea S, et al. Racial/ethnic differences in subclinical atherosclerosis among adults with diabetes. The Multiethnic Study of Atherosclerosis. Diabetes Care. 2005;28:2768-2770.
11. Bild DE, Detrano R, Peterson D, et al. Ethnic differences in coronary calcification. The Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2005;111:1313-1320.
12. Budoff MJ, Nasir K, Mao S, et al. Ethnic differences of the presence and severity of coronary atherosclerosis. Atherosclerosis. 2006;187:343-350.
13. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation. 2004;110:738-743.
14. Okosun IS, Choi ST, Boltri JM, et al. Trends in abdominal adiposity in white, black, and Mexican-American adults, 1988-2000. Obes Res. 2003;11:1010-1017.
15. Centers for Disease Control and Prevention. Racial/ethnic disparities in prevalence, treatment, and control of hypertension: United States, 1999-2002. Morb Mortal Wkly Rep. 2005;54:7-9.
16. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
17. Jones DW, Chambless LE, Folsom AR, et al. Risk factors for coronary heart disease in African Americans: the Atherosclerosis Risk in Communities Study, 1987-1997. Arch Intern Med. 2002;162:2565-2571.
18. Whittle JC, Whelton PK, Seidler AJ, et al. Does racial variation in risk factors explain black-white differences in the incidence of hypertensive end-stage renal disease? Arch Intern Med. 1991;151:1359-1364.
19. U.S. Renal Data System. Excerpts from the USRDS 2006 Annual Data Report. Am J Kidney Dis. 2007;49:S1-S296.
20. Bonow RO, Bohannon N, Hazzard W. Risk stratification in coronary artery disease and special populations. Am J Med. 1996;101(suppl 4A):417S-424S.
21. Hall, WD, Clark LT, Wanger NK, et al. The metabolic syndrome in African Americans: a review. Ethn Dis. 2003;13:414-428.
22. Hutchinson RG, Watson RL, Davis CE, et al, for the ARIC Study Group. Racial differences in risk factors for atherosclerosis: the ARIC study. Angiology. 1997;48:279-290.
23. Sharma S, Malarcher AM, Giles WH, et al. Racial, ethnic and socioeconomic disparities in the clustering of cardiovascular disease risk factors. Ethn Dis. 2004;14:43-48.
24. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutritional Examination Survey. JAMA. 2002;287:356-359.
25. Palaniappan L, Carnethon MR, Wang Y, et al, for the Insulin Resistance Atherosclerosis Study. Predictors of the incident metabolic syndrome in adults: the Insulin Resistance Atherosclerosis Study. Diabetes Care. 2004;27:788-793.
26. Patt MR, Yanek LR, Moy TF, et al. Assessment of global coronary heart disease risk in overweight and obese African-American women. Obes Res. 2003;11:660-667.
27. Bacha F, Saad R, Gungor N, et al. Obesity, regional fat distribution, and syndrome X in obese black versus white adolescents: race differential in diabetogenic and atherogenic risk factors. J Clin Endocrinol Metab. 2003;88:2534-2540.
28. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the US population, 1971-1993. Diabetes Care. 1998;21:1138-1145.
29. Brancati FL, Kao WHL, Folsom AR, et al. Incident type 2 diabetes mellitus in African American and white adults. The Atherosclerosis Risk in Communities Study. JAMA. 2000;283:2253-2259.
30. Ham's MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults: the Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998;21:518-524.
31. Karter AJ, Ferrara A, Liu JY, et al. Ethnic disparities in diabetic complications in an insured population. JAMA. 2002;287:2519-2527.
32. Harris MI. Health care and health status and outcomes for patients with type 2 diabetes. Diabetes Care. 2000;23:754-758.
33. Sharma MD, Pavlik VN. Dyslipidaemia in African Americans, Hispanics, and whites with type 2 diabetes mellitus and hypertension. Diabetes Obes Metab. 2001;3:41-45.
34. Chaiken RL, Banerji MA, Huey H, et al. Do blacks with NIDDM have an insulin-resistant syndrome? Diabetes. 1993;42:444-449.
35. Banerji MA, Lebovitz HE. Insulin action in black Americans with NIDDM. Diabetes Care. 1992;15:1295-1302.
36. Chaiken RL, Banerji MA, Pasmantier R, et al. Patterns of glucose and lipid abnormalities in black NIDDM subjects. Diabetes Care. 1991;14:1036-1042.
37. Banerji MA, Lebovitz HE. Coronary heart disease risk factor profiles in black patients with non-insulin-dependent diabetes mellitus: paradoxic patterns. Am J Med. 1991;91:51-58.
38. American Diabetes Association. Hypertension management in adults with diabetes. Diabetes Care. 2004;27(suppl 1):S65-S67.
39. Bakris GL, Williams M, Dworkin L, et al, for the National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000;36:646-661.
40. Douglas JG, Bakris GL, Epstein M, et al. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hyperstension in Blacks. Arch Intern Med. 2003;163:525-541.
41. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med. 1997;336:1117-1124.
42. Sacks FM, Svetkey LP, Vollmer WM, et al, for the DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med. 2001;344:3-10.
43. Vollmer WM, Sacks FM, Ard J, et al. Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-Sodium Trial. Ann Intern Med. 2001;135:1019-1028.
44. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-2752.
45. O'Meara JG, Kardia SL, Armon JJ, et al. Ethnic and sex differences in the prevalence, treatment, and contril of dyslipidemia among hypertensive adults in the GENOA study. Arch Intern Med. 2004;164:13130-1318.
46. Grundy SM, Cleeman JI, Bairey Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239.
47. Cook CB, Erdman DM, Ryan GJ, et al. The pattern of dyslipidemia among urban African-Americans with type 2 diabetes. Diabetes Care. 2000;23:319-324.
48. Haffner SM. The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease. Diabetes Care. 1997;20:469-471.
49. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol And Recurrent Events (CARE) trial. Circulation. 1998;98:2513-2519.
50. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005-2016.
51. Colhoun HM, Betteridge DJ, Durrington PN, et al, on behalf of the CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-696.
52. Lipitor (atorvastatin calcium) [package insert]. New York, NY: Pfizer; September 2005.
53. Mevacor (lovastatin) [package insert]. Whitehouse Station, NJ: Merck & Co; November 2004.
54. Pravachol (pravastatin sodium) [package insert]. Princeton, NJ: Bristol-Myers Squibb; December 2004.
55. Zocor (simvastatin) [package insert]. Whitehouse Station, NJ: Merck & Co; November 2004.
56. Lescol (fluvastatin) [package insert]. East Hanover, NJ: Novartis; April 2006.
57. Crestor (rosuvastatin calcium) [package insert], Wilmington, DE: Astra-Zeneca; January 2005.
58. Jacobson TA, Chin MM, Curry CL, et al. Efficacy and safety of pravastatin in African Americans with primary hypercholesterolemia. Arch Intern Med. 1995;155:1900-1906.
59. Ferdinand KC, Clark LT, Watson KE, et al, for the ARIES Study Group. Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial. Am J Cardiol. 2006;97:229-235.
60. Simon JA, Lin F, Hulley SB, et al. Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) study. Am J Cardiol. 2006;97:843-850.
61. Rodney RA, Sugimoto D, Wagman B, et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in African-American patients with primary hypercholesterolemia. J Natl Med Assoc. 2006;98:772-778.
62. Clark LT, Maki KC, Galant R, et al. Ethnic differences in achievement of cholesterol treatment goals. Results from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology II. J Gen Intern Med. 2006;21:320-326.
63. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003;92:152-160.
64. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemia hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:2998-3007.
65. Jawa A, Nachimuthu S, Pendergrass M, et al. Impaired vascular reactivity in African-American patients with type 2 diabetes mellitus and microalbuminuria or proteinuria despite angiotensin-converting enzyme inhibitor therapy. J Clin Endocrinol Metab. 2006;91:31-35.
66. Gainer JV, Morrow JD, Loveland A, et al. Effect of bradykinin-receptor blockade on the response to angiofensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med. 1998;339:1285-1292.
67. Vidt DG, Harris S, McTaggart F, et al. Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate. Am J Cardiol. 2006;97:1602-1606.
68. Ferdinand KC. Isosorbide dinitrate and hydralazine hydrochloride: a review of efficacy and safety. Expert Rev Cardiovasc Ther. 2005;3:993-1001.
69. Thomas AJ, Eberly LE, Smith GD, et al, for the Multiple Risk Factor Intervention Trial Research Group. Race/ethnicity, income, major risk factors, and cardiovascular disease mortality. Am J Public Health. 2005;95:1417-1423.
70. Fiscella K, Franks P, Gold M, et al. Inequality in quality: addressing socioeconomic, racial, and ethnic disparities in health care. JAMA. 2000;289:2579-2584.
71. Strike PC, Steptoe A. Psychosocial factors in the development of coronary artery disease. Prog Cardiovasc Dis. 2004;46:337-347.